This company has been marked as potentially delisted and may not be actively trading. Medicis Pharmaceutical (MRX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesOptions ChainOwnershipTrendsBuy This Stock MRX vs. BGC, SNEX, FRGE, TOP, GSIW, ICE, CME, NDAQ, TW, and LPLAShould you be buying Medicis Pharmaceutical stock or one of its competitors? The main competitors of Medicis Pharmaceutical include BGC Group (BGC), StoneX Group (SNEX), Forge Global (FRGE), TOP Financial Group (TOP), Garden Stage (GSIW), Intercontinental Exchange (ICE), CME Group (CME), Nasdaq (NDAQ), Tradeweb Markets (TW), and LPL Financial (LPLA). These companies are all part of the "security & commodity brokers, dealers, exchanges & services" industry. Medicis Pharmaceutical vs. BGC Group StoneX Group Forge Global TOP Financial Group Garden Stage Intercontinental Exchange CME Group Nasdaq Tradeweb Markets LPL Financial BGC Group (NASDAQ:BGC) and Medicis Pharmaceutical (NYSE:MRX) are both mid-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends. Is BGC or MRX a better dividend stock? BGC Group pays an annual dividend of $0.08 per share and has a dividend yield of 0.9%. Medicis Pharmaceutical pays an annual dividend of $0.56 per share and has a dividend yield of 1.6%. BGC Group pays out 30.8% of its earnings in the form of a dividend. Is BGC or MRX more profitable? BGC Group has a net margin of 5.59% compared to Medicis Pharmaceutical's net margin of 0.00%. BGC Group's return on equity of 47.55% beat Medicis Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets BGC Group5.59% 47.55% 11.71% Medicis Pharmaceutical N/A N/A N/A Does the media prefer BGC or MRX? In the previous week, BGC Group had 5 more articles in the media than Medicis Pharmaceutical. MarketBeat recorded 5 mentions for BGC Group and 0 mentions for Medicis Pharmaceutical. BGC Group's average media sentiment score of 0.63 beat Medicis Pharmaceutical's score of 0.00 indicating that BGC Group is being referred to more favorably in the media. Company Overall Sentiment BGC Group Positive Medicis Pharmaceutical Neutral Which has preferable earnings & valuation, BGC or MRX? Medicis Pharmaceutical has lower revenue, but higher earnings than BGC Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBGC Group$2.21B2.02$126.99M$0.2635.46Medicis Pharmaceutical$1.24B2.01$141.30MN/AN/A Does the MarketBeat Community favor BGC or MRX? BGC Group received 164 more outperform votes than Medicis Pharmaceutical when rated by MarketBeat users. However, 67.37% of users gave Medicis Pharmaceutical an outperform vote while only 59.81% of users gave BGC Group an outperform vote. CompanyUnderperformOutperformBGC GroupOutperform Votes32359.81% Underperform Votes21740.19% Medicis PharmaceuticalOutperform Votes15967.37% Underperform Votes7732.63% Do institutionals & insiders believe in BGC or MRX? 52.1% of BGC Group shares are held by institutional investors. 26.3% of BGC Group shares are held by insiders. Comparatively, 3.8% of Medicis Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend BGC or MRX? BGC Group presently has a consensus price target of $16.00, suggesting a potential upside of 73.54%. Medicis Pharmaceutical has a consensus price target of $35.00, suggesting a potential downside of 1.59%. Given BGC Group's stronger consensus rating and higher possible upside, research analysts clearly believe BGC Group is more favorable than Medicis Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGC Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Medicis Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 SummaryBGC Group beats Medicis Pharmaceutical on 12 of the 17 factors compared between the two stocks. Remove Ads Get Medicis Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRX vs. The Competition Export to ExcelMetricMedicis PharmaceuticalSecurity & commodity brokers IndustryFinance SectorNYSE ExchangeMarket Cap$2.73B$28.96B$11.31B$19.48BDividend Yield1.44%1.47%5.40%3.76%P/E RatioN/A18.9922.6433.08Price / Sales2.017.0825.6026.21Price / CashN/A21.1217.6117.55Price / BookN/A4.722.704.56Net Income$141.30M$1.00B$1.03B$1.02B Medicis Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRXMedicis Pharmaceutical0.6494 of 5 stars$35.56+9.3%$35.00-1.6%N/A$2.73B$1.24B0.002,074Gap UpBGCBGC Group3.5754 of 5 stars$9.70+3.7%$16.00+64.9%+108.1%$4.68B$2.21B37.313,895SNEXStoneX Group2.5888 of 5 stars$79.15+1.2%N/A+65.6%$2.54B$108.25B9.463,600Short Interest ↑High Trading VolumeFRGEForge Global2.6714 of 5 stars$0.62+0.2%$4.50+625.8%-68.8%$116.65M$78.66M-1.443Stock SplitTOPTOP Financial Group0.4483 of 5 stars$1.28+0.8%N/A-55.5%$47.40M$2.73M0.0011Positive NewsGSIWGarden Stage1.1217 of 5 stars$0.48+0.5%N/A-92.3%$7.55M$1.31M0.0013Short Interest ↓Positive NewsGap UpICEIntercontinental Exchange4.4752 of 5 stars$175.27+0.5%$178.80+2.0%+25.0%$100.70B$11.76B36.6712,920Short Interest ↓Analyst RevisionPositive NewsCMECME Group4.0547 of 5 stars$262.94-0.2%$238.93-9.1%+23.7%$94.75B$6.13B27.193,460Positive NewsNDAQNasdaq4.7624 of 5 stars$77.41+2.5%$86.88+12.2%+22.1%$44.52B$7.40B40.328,525Positive NewsTWTradeweb Markets3.7627 of 5 stars$144.08+1.2%$138.50-3.9%+42.9%$34.03B$1.73B61.841,412Positive NewsLPLALPL Financial4.8885 of 5 stars$341.74+4.2%$379.17+11.0%+25.7%$25.52B$12.39B24.346,900Positive News Remove Ads Related Companies and Tools Related Companies BGC Competitors SNEX Competitors FRGE Competitors TOP Competitors GSIW Competitors ICE Competitors CME Competitors NDAQ Competitors TW Competitors LPLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MRX) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Tax Shock?Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicis Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicis Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRX Stock Free MRX Stock Alerts